Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
Daiichi Sankyo Eclipses Takeda, Becomes Top Maker by Japan Ethical Drug Sales
Daiichi Sankyo overtook Takeda Pharmaceutical by a whisker to top the ranking of ethical drug sales in Japan among Japanese makers in the year ended March 2017. Daiichi Sankyo said on May 11 that it rang up ethical drug sales…
To read the full story
Related Article
- Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
May 1, 2018
- Daiichi Sankyo Ekes Out 2.5% Sales Rise despite Olmetec LOE, Operating Profit Sags 33.5%
November 1, 2017
- Daiichi Sankyo Earnings Lower on Yen Moves; Olmesartan Suffers 21.8% Slide
November 1, 2016
- Daiichi Sankyo Sees 7.3% Sales Rise, but Girding for FY2016 Dip on Olmesartan Cliff
May 13, 2016
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…